


Full Text
OVID

JOURNAL OF
Immunotherapy

**WEB-BASED MANUSCRIPT
SUBMISSION NOW AVAILABLE!**
See journal website for details.
www.immunotherapy-journal.com

Jeonbuk National University
ISSN : 1524-9557
Journal of Immunotherapy
VOL. 44 NO. 6

 WILL JOURNAL INC.



1524-9557(202107/202108)44:6:1-W

OPEN open access article

Contents

Basic Study

- 209 The Intracellular Domain of CD40 is a Potent Costimulatory Element in Chimeric Antigen Receptors**
Ofir Levin-Piaeda, Noam Levin, Sarah Pozner, Adi Danieli, Hadas Weinstein-Marom, and Gideon Gross

Clinical Studies

- 214 PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM)**
Shuguang Zhang, Kun Chen, Huanmei Liu, Changyou Jing, Xinxin Zhang, Chunfeng Qu, and Shengji Yu
- OPEN 224 Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis**
Charles Lance Cowey, Emilie Scherrer, Marley Boyd, Kathleen M. Aguilar, April Beeks, and Clemens Krepler

(continued next page)



Journal of Immunotherapy (ISSN 1524-9557) is published monthly except for combined issues in February/March, July/August, and November/December by Wolters Kluwer Health, Inc at 1800 Dual Highway, Suite 201, Hagerstown, MD 21740-6636. Periodicals postage paid at Hagerstown, MD and additional mailing offices. POSTMASTER: Send address changes to *Journal of Immunotherapy*, PO Box 1610, Hagerstown, MD 21740. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Annual Subscription Rates: *United States* - \$1044 Individual, \$4224 Institution, \$461 In-training. *Rest of World* - \$1169 Individual, \$4836 Institution, \$461 In-training. Single copy rate \$557. All prices include a handling charge. Subscriptions outside of North America must add \$24 for airfreight delivery. United States residents of AL, CO, DC, FL, GA, HI, IA, ID, IN, KS, KY, LA, MD, MO, ND, NM, NV, PR, RI, SC, SD, UT, VT, WA, WV add state sales tax. The GST tax of 7% must be added to all orders shipped to Canada (Wolters Kluwer Health, Inc.'s GST Identification #895524239, Publications Mail Agreement #616346). Subscription prices outside the United States must be prepaid. Prices subject to change without notice. Visit us online at www.lww.com.

Website: www.immunotherapy-journal.com

Contents *(continued)*

- 234 Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series**
Sophia Z. Shalhout, Howard L. Kaufman, Ryan J. Sullivan, Donald Lawrence, and David M. Miller
- 239 Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients**
Oana D. Persa, Kerstin Schatton, Albert Rübben, Carola Berking, Michael Erdmann, Max Schlaak, Cornelia Mauch, and Theresa Steeb

The In

Summary: The generation and strongly influen generation and domain of the comparison with of both generati the NF- κ B sign: was comparab tion markers, mediating targe pattern of T cell were evident. W domain is a pot and third-gener:

Key Words: CA and third gener

(J Immunothe

In an attempt antigen rece are being ma ments incorp generation an 4-1BB have b derived from others have al

A numbe expressed by : capacity of Cl effects includi mentation of apoptotic sign from exhausti mediated supp different mole capacity of t reprogrammed ment of a wide we demonstra homo-oligome

This journal is listed in *Index Medicus/MEDLINE Current Contents/Life Sciences Scisearch, Biomedical Database, BIOSIS, EMBASE/Excerpta Medica, Chemical Abstracts, and Current Awareness in Biological Sciences.*

Address for subscription information, orders, or change of address: 1800 Dual Highway, Suite 201, Hagerstown, MD 21740-6636; phone 800-638-3030; fax 301-223-2400.

Wolters Kluwer Health, Inc. cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. The appearance of advertising in this journal does not constitute an endorsement or approval by Wolter Kluwer Health, Inc. for the quality or value of the product advertised or of the claims made for it by its manufacturer.

Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the "Get Content & Permissions" link under the "Article Tools" box that appears on the right side of the page. For questions about the Rightslink service, e-mail customer-care@copyright.com or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on author's permission requests are available at <https://shop.lww.com/journal-permission>. For additional permission inquiries, please contact Permissions@LWW.com.

For translation rights requests, contact TranslationRights@wolterskluwer.com. For license to republish and distribute requests, contact HealthLicensing@wolterskluwer.com. For special projects and reprints (U.S./Canada), contact Alan Moore at Alan.Moore@wolterskluwer.com or reprintsolutions@wolterskluwer.com. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at Avia.Potashnik@wolterskluwer.com or InternationalReprints@wolterskluwer.com.

Article and issue photocopies and 16-mm microfilm, 35-mm microfilm, and 105-mm microfiche are available from UMI, 300 North Zeeb Road, Ann Arbor, MI 48106-1346.

Received for pub From the *Immi tute, Kiryat S Upper Galile Germany. H.W.-M. and G. Reprints: Gideon Research Ins (e-mail: gidi@) Copyright © 202

J Immunother